We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

24 hedge funds and large institutions have $254K invested in Matinas BioPharma in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $166K → $254K (+$87.7K)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.86% less ownership

Funds ownership: 6.29% → 5.43% (-0.86%)

4% less funds holding

Funds holding: 25 → 24 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
24
Holders Change
-1
Holders Change %
-4%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$6.41K
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.69K
3
Raymond James Financial
Raymond James Financial
Florida
+$234
4
Jones Financial Companies
Jones Financial Companies
Missouri
+$44
5
Bank of America
Bank of America
North Carolina
+$4

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13.3K
2
TSS
Two Sigma Securities
New York
-$10.9K
3
SIG
Sargent Investment Group
Maryland
-$4.53K
4
UBS Group
UBS Group
Switzerland
-$1.12K
5
JP Morgan Chase
JP Morgan Chase
New York
-$470
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$53.2K – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$49.4K +$6.41K +8,753 +19%
BlackRock
3
BlackRock
New York
$44.2K – – –
HIW
4
Holos Integrated Wealth
Pennsylvania
$36.7K – – –
SIG
5
Sargent Investment Group
Maryland
$32.1K -$4.53K -6,180 -15%
Renaissance Technologies
6
Renaissance Technologies
New York
$22K +$1.69K +2,300 +10%
State Street
7
State Street
Massachusetts
$13.6K – – –
TRCT
8
Tower Research Capital (TRC)
New York
$981 -$4 -6 -0.5%
Bank of America
9
Bank of America
North Carolina
$873 +$4 +6 +0.6%
Raymond James Financial
10
Raymond James Financial
Florida
$285 +$234 +320 New
Osaic Holdings
11
Osaic Holdings
Arizona
$185 – – –
CAM
12
Costello Asset Management
Pennsylvania
$178 – – –
Morgan Stanley
13
Morgan Stanley
New York
$128 – – –
UBS Group
14
UBS Group
Switzerland
$98 -$1.12K -1,530 -93%
Wells Fargo
15
Wells Fargo
California
$91 – – –
Jones Financial Companies
16
Jones Financial Companies
Missouri
$55 +$44 +60 New
SPIA
17
Steward Partners Investment Advisory
New York
$54 – – –
EWA
18
EverSource Wealth Advisors
Alabama
$53 – – –
VFM
19
Vision Financial Markets
Connecticut
$36 – – –
RIL
20
Rothschild Investment LLC
Illinois
$12 – – –
SS
21
SBI Securities
Japan
$10 -$1 -2 -15%
FFA
22
Farther Finance Advisors
California
$4 – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$2 +$1 +1 +100%
MCM
24
MAI Capital Management
Ohio
$2 +$1 +2 New
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
– -$13.3K -25,610 Closed
1
2

MTNB Hedge Fund Activity: Q2 2025 in Review

24 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2025, worth a combined $254K — up 53% from $166K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MTNB and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $6.41K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $13.3K sold.

  • 24 institutional investors held Matinas BioPharma (MTNB) as of Q2 2025, down from 25 in Q1 2025.
  • Funds reported $254K of Matinas BioPharma stock for Q2 2025, up 53% quarter-over-quarter.
  • 3 funds opened new Matinas BioPharma positions in Q2 2025 and 4 closed out, a net change of -1 holder.
  • The largest Matinas BioPharma buyer in Q2 2025 was Geode Capital Management, an estimated $6.41K added.
  • The largest Matinas BioPharma seller in Q2 2025 was Susquehanna International Group, an estimated $13.3K sold.

Based on aggregated 13F filings for Q2 2025.